Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study

• Published in: Diagnostic microbiology and infectious disease 2011-03, Vol.69 (3), p.291-306
• Main Authors: Zhanel, George G, Adam, Heather J, Low, Donald E, Blondeau, Joseph, DeCorby, Melanie, Karlowsky, James A, Weshnoweski, Barbara, Vashisht, Ravi, Wierzbowski, Aleksandra, Hoban, Daryl J
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - pharmacology; Antimicrobial; Bacterial Infections - microbiology; beta-Lactamases; Canada; Child; Child, Preschool; Drug Resistance, Bacterial; Escherichia coli; Gram-Negative Bacteria - drug effects; Gram-Negative Bacteria - isolation & purification; Gram-Positive Cocci - drug effects; Gram-Positive Cocci - isolation & purification; Hospitals; Humans; Infant; Infant, Newborn; Infectious Disease; Internal Medicine; Methicillin-Resistant Staphylococcus aureus - drug effects; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Staphylococcus aureus; Susceptibility; Vancomycin Resistance
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2010.10.025

Abstract The CANWARD study (Canadian Ward Surveillance Study) assessed the antimicrobial susceptibility of a variety of available agents against 15 644 pathogens isolated from patients in Canadian hospitals between 2007 and 2009. The most active (based on MIC data) agents against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci were daptomycin, linezolid, tigecycline, and vancomycin (MRSA only) with MIC90 's (μg/mL) of 0.25 and 2, 2 and 2, 0.5 and 0.12, and 1, respectively. The most active agents against extended-spectrum β-lactamase–producing Escherichia coli were colistin (polymyxin E), doripenem, ertapenem, meropenem, and tigecycline with MIC90 's (μg/mL) of 1, ≤0.12, 0.25, ≤0.12, and 1, respectively. The most active agents against Pseudomonas aeruginosa were amikacin, cefepime, ceftazidime, colistin, doripenem, meropenem, and piperacillin-tazobactam with MIC90 's (μg/mL) of 32, 16, 32, 2, 4, 8, and 64, respectively. Overall, the most active agents versus Gram-positive cocci from Canadian hospitals were vancomycin, linezolid, daptomycin, and tigecycline and versus Gram-negative bacilli were amikacin, cefepime, doripenem, ertapenem (excluding Pseudomonas aeruginosa ), meropenem, piperacillin-tazobactam, and tigecycline (excluding Pseudomonas aeruginosa ).